Coherus BioSciences has received FDA approval for Udenyca (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC) for patients with cancer receiving myelosuppressive chemotherapy. Udenyca is Coherus’ first drug to receive FDA or EC approval. “We are excited to announce that Coherus has received FDA approval for Udenyca. I want to thank…